| Domain | Established finding | Quantitative/clinical detail | Ontology suggestions | Evidence strength/key source |
|---|---|---|---|---|
| Disease identity | Short stature, microcephaly, and endocrine dysfunction corresponds to an XRCC4-related Mendelian disorder | MONDO:0014686; Open Targets links the disease to **XRCC4** as the associated target | MONDO:0014686; XRCC4 (HGNC:12831) | Strong disease-target mapping (pqac-00000000) |
| Core molecular cause | Biallelic **XRCC4** defects impair canonical non-homologous end joining (NHEJ) DNA double-strand break repair | XRCC4 is a core NHEJ factor acting with LIG4/XLF; human disease established by multiple affected individuals with pathogenic XRCC4 variants causing primordial dwarfism/microcephaly | GO:0006302 DNA ligation involved in DNA repair; GO:0006974 cellular response to DNA damage stimulus; GO:0000724 double-strand break repair via NHEJ | Strong primary human genetic + cellular evidence, Murray 2015 (pqac-00000003, pqac-00000009) |
| Inheritance | Autosomal recessive inheritance is established | Affected families include consanguineous pedigrees and homozygous/compound heterozygous XRCC4 variants in the 2015 cohort; endocrine pedigree also reported as familial recessive in reviews | HP:0000007 Autosomal recessive inheritance | Strong primary/review support (pqac-00000001, pqac-00000003) |
| Prenatal/postnatal growth failure | Prenatal and postnatal growth retardation are core features | Murray cohort: “all XRCC4-MPD-affected individuals demonstrated in utero and postnatal growth retardation”; severe short stature/dwarfism recurrent across reports | HP:0001511 Growth delay; HP:0000252 Microcephaly-associated primordial dwarfism phenotype; UBERON:0002101 limb/long bone growth context | Strong primary cohort evidence (pqac-00000011, pqac-00000015) |
| Progressive microcephaly | Microcephaly is present at birth and becomes more pronounced postnatally | Murray cohort: microcephaly at birth with disproportionate worsening after birth; brain growth appears especially sensitive to unrepaired DNA damage | HP:0000252 Microcephaly; HP:0011451 Progressive microcephaly; UBERON:0000955 brain | Strong primary cohort evidence (pqac-00000011, pqac-00000013) |
| Neurodevelopment | Developmental delay is variable, not universal | Murray cohort included none to severe developmental delay; mechanism inferred to involve impaired neurogenesis and apoptosis of developing neural cells | HP:0001263 Global developmental delay; HP:0011344 Severe global developmental delay; CL:0000034 neural stem cell; CL:0000540 neuron | Moderate-strong human cohort + mechanistic support (pqac-00000015, pqac-00000006) |
| Endocrine dysfunction | Endocrine manifestations are part of the named disease entity but appear limited in the published XRCC4 literature | Review evidence cites a family with **severe short stature, gonadal failure, and early-onset metabolic syndrome** due to an XRCC4 splice mutation; these findings are not described as common in the larger Murray cohort | HP:0008209 Premature ovarian insufficiency/gonadal dysfunction (approximate); HP:0000824 Abnormality of the gonad; HP:0001943 Metabolic syndrome | Limited/heterogeneous evidence; mainly de Bruin 2015 as summarized in review, not broadly replicated (pqac-00000001) |
| Gonadal failure/metabolic syndrome | Likely real but currently narrow phenotype extension rather than universally established core feature | Reported in a single family in review text; should be treated as **limited evidence** and possibly allelic/variant-specific until additional cases are published | HP:0000135 Hypogonadism/gonadal failure related term; HP:0001956 Metabolic abnormality | Limited evidence/inference from cited pedigree summary (pqac-00000001) |
| Immune phenotype | Overt immunodeficiency is usually absent despite NHEJ deficiency | Most individuals had normal blood counts, T/B-cell subsets, and immunoglobulins; one patient had chronic non-progressive lymphopenia; normal vaccine responses documented in P1 | HP:0002721 Immunodeficiency (not typical/usually absent); HP:0001888 Lymphopenia | Strong primary cohort evidence (pqac-00000002, pqac-00000010) |
| V(D)J recombination | Adaptive immunity is functionally preserved but junctional diversity is perturbed | Deep sequencing showed large numbers of unique productive IGH rearrangements, but significantly reduced random nucleotide insertions at V(D)J junctions | GO:0033151 V(D)J recombination; GO:0043966 histone H2AX phosphorylation (damage response marker context) | Strong primary mechanistic evidence (pqac-00000002, pqac-00000009) |
| Radiosensitivity | Patient cells are hypersensitive to ionizing radiation | After irradiation, **99.4% of P1** and **62.3% of P5** asynchronous cells retained >5 γ-H2AX foci at 24 h versus **9.2%** of controls; **58% ± 6.0%** of DSBs remained unresolved in P1 cells versus **5.4% ± 2.6%** in controls | HP:0011297 Increased cellular sensitivity to ionizing radiation; GO:0000785 chromatin, GO:0006974 response to DNA damage | Strong quantitative primary cellular evidence (pqac-00000010, pqac-00000011) |
| Environmental information | No environmental cause is established, but ionizing radiation is a clinically important hazard | Authors recommend minimizing clinical X-ray exposure because of marked cellular radiosensitivity | CHEBI:36927 ionizing radiation (exposure concept); NCIT:C16548 Radiation Exposure | Strong management implication from primary cellular data (pqac-00000005, pqac-00000013) |
| Anatomy affected | Primary affected systems are developing brain and generalized somatic growth; secondary/occasional involvement may include gonads, kidneys, genital tract | Human cohort includes brain growth failure, proportionate small body size, variable developmental delay; occasional additional features in tables/reviews include renal/genital anomalies | UBERON:0000955 brain; UBERON:0002103 kidney; UBERON:0000991 gonad; UBERON:0000473 neuroepithelium | Moderate evidence; primary for brain/growth, limited for gonadal/renal extensions (pqac-00000011, pqac-00000010, pqac-00000001) |
| Diagnosis | Diagnosis is molecular, supported by phenotype plus sequencing and functional interpretation | Exome sequencing/cohort resequencing identified XRCC4 variants; supportive findings include prenatal/postnatal growth failure, microcephaly, variable delay, and cellular radiosensitivity; differential includes other NHEJ disorders such as **LIG4**, **NHEJ1/XLF**, **DCLRE1C/Artemis**, **PRKDC** | NCIT:C101294 Whole Exome Sequencing; NCIT:C47809 Molecular Diagnosis; HP:0000252; HP:0001511 | Strong primary diagnostic framework (pqac-00000003, pqac-00000008) |
| Differential diagnosis | Closest differentials are DNA repair/NHEJ syndromes and primordial dwarfism disorders | XRCC4 differs from LIG4/NHEJ1 by often lacking overt SCID; other microcephalic dwarfism syndromes remain differential diagnoses | MONDO terms for DNA repair disorders; HP:0002721; HP:0001511 | Moderate evidence/inference from comparative discussion (pqac-00000009, pqac-00000001) |
| Treatment/management | No disease-modifying therapy is established; management is supportive and preventive | Current care is developmental support, surveillance of growth and neurologic status, endocrine replacement if endocrine failure is documented, infection/hematology monitoring as indicated, and avoidance/minimization of diagnostic radiation; no disease-specific clinical trial identified in prior tool search | NCIT:C15783 Supportive Care; NCIT:C15604 Physical Therapy; NCIT:C15220 Hormone Replacement Therapy; NCIT:C94626 Genetic Counseling | Moderate evidence: supportive management inferred from phenotype and radiosensitivity; no approved targeted therapy (pqac-00000013, pqac-00000012) |
| Prognosis | Natural history is incompletely defined; childhood survival is compatible, but long-term cancer risk is uncertain | Murray cohort was young and had no observed tumors, yet authors note cancer risk is probably elevated because of radiosensitivity and analogy to other NHEJ disorders | HP:0000006 Autosomal recessive disease course context; NCIT:C17021 Disease Progression | Limited evidence/important uncertainty (pqac-00000013, pqac-00000015) |
| Population/epidemiology | Extremely rare disorder; prevalence/incidence unavailable | Only a small number of families/patients are reported in the literature; no robust population estimate located | MONDO:0014686 | Unavailable data; rarity inferred from case-based literature (pqac-00000001, pqac-00000003) |
| Mouse models | Mouse data support neurodevelopmental vulnerability and explain preserved immunity in residual-function states | **Xrcc4-null** mice are embryonic lethal because of apoptosis of post-mitotic neurons; **Xrcc4M61R** separation-of-function mice are DNA-repair deficient with minor adaptive immune impact, while combined deficiency with **Xlf/Paxx/Atm** causes severe immunodeficiency | MGI:Xrcc4; GO:0006915 apoptosis; CL:0000540 neuron; CL:0000813 memory B cell/T-cell lineage context | Strong model-organism evidence (pqac-00000007) |
| 2023-2024 research context | Recent work reinforces DDR-linked microcephaly mechanisms rather than introducing XRCC4-specific therapy | 2023 review emphasizes that DNA repair defects trigger reduced proliferation, premature differentiation, and apoptosis of neural progenitors causing microcephaly; 2024 ovarian DNA-repair work supports biologic plausibility for gonadal vulnerability but is not XRCC4-syndrome-specific | GO:0008283 cell proliferation; GO:0072331 signal transduction involved in DNA integrity checkpoint; CL:0000047 oocyte | Moderate contextual evidence; mechanistic relevance but partly indirect (pqac-00000006) |


*Table: This table compacts the strongest available human, cellular, and mouse evidence for XRCC4-related short stature, microcephaly, and endocrine dysfunction. It highlights which features are well established, which remain limited or inferred, and which data are currently unavailable.*